BRAF
ENSG00000157764
Target class
Kinase
Chromosome
7
Approved drugs
6
Clinical candidates (approved and in development)
17
- Approved drugs
- 6
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- Yes
- Target name
- BRAF
- Gene name
- B-Raf proto-oncogene, serine/threonine kinase
- Gene symbol
- BRAF
- Protein name
- Serine/threonine-protein kinase B-raf (EC 2.7.11.1) (Proto-oncogene B-Raf) (p94) (v-Raf murine sarcoma viral oncogene homolog B1)
- BRAF1
- BRAF-1
- Gene biotype
- Protein coding
- Gene family
- Mitogen-activated protein kinase kinase kinases|RAF family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 27.58
- Tissue specificity (Gini)
- 0.264
- Tissue specificity (tau)
- 0.613
- KEGG gene identifiers
- hsa:673
- Protein interaction confidence
- 0.867087
- Protein interaction partners
- 92
- R-HSA-1295596
- R-HSA-170968
- R-HSA-170984
- R-HSA-187706
- R-HSA-5673000
- R-HSA-5674135
- R-HSA-5674499
- R-HSA-5675221
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-9649948
- R-HSA-9656223
- R-HSA-9726840
- R-HSA-9726842
- End position
- 140924976
- Start position
- 140719327
- Chromosome
- 7
- Strand
- Reverse
- Nucleus . Cytoplasm . Cell membrane . Note=Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes. .
- Cytosol
- End piece
- Mid piece
- Plasma membrane
- Principal piece
- Vesicles
Publication evidence
- PubMed 19710016
- Tissue specificity (tau)
- 0.61331
- Expression inequality (Gini)
- 0.264197
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 27.58
- Brain - Cerebellum
- 21.49
- Testis
- 20.28
- Thyroid
- 17.94
- Uterus
- 17.04
Expression in transcripts per million
- Brain - Cerebellar Hemisphere27.58
- Brain - Cerebellum21.49
- Testis20.28
- Thyroid17.94
- Uterus17.04
- Ovary16.94
- Fallopian Tube16.7
- Nerve - Tibial16.65
- Cells - EBV-transformed lymphocytes16.32
- Artery - Tibial15.83
- Lung15.59
- Cervix - Endocervix15.54
- Pituitary14.88
- Cervix - Ectocervix14.82
- Skin - Sun Exposed (Lower leg)14.05
- Skin - Not Sun Exposed (Suprapubic)13.69
- Vagina13.57
- Prostate13.49
- Artery - Aorta12.96
- Bladder12.95
- Breast - Mammary Tissue12.92
- Colon - Sigmoid12.66
- Adipose - Subcutaneous12.52
- Brain - Frontal Cortex (BA9)11.98
- Esophagus - Muscularis11.93
And 29 more, listed on the interactive page.
- GO:0000165
- GO:0006468
- GO:0007173
- GO:0009887
- GO:0010628
- GO:0010828
- GO:0033138
- GO:0043066
- GO:0070374
- GO:0071277
- GO:0090150
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0004672
- GO:0004674
- GO:0004708
- GO:0005509
- GO:0005515
- GO:0031267
- GO:0042802
- GO:0097110
- GO:0106310
heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Anti-apoptotic; preserves left ventricular function under stress. Knockout mouse model: left ventricular dysfunction and heart failure in the absence of additional stress; Dominant negative transgenic mouse model: reduced hypertrophy but left ventricular dysfunction due to cell death
Biological samples
- cardiovascular system
PubMed 21283106
Related records
Trials (1,481)
- "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
Drugs (20)
- ARQ-736 Serine/threonine-protein kinase B-raf inhibitor
- ARQ-736 FREE ACID Serine/threonine-protein kinase B-raf inhibitor
- Belvarafenib RAF serine/threonine protein kinase inhibitor
- CEP-32496 Serine/threonine-protein kinase B-raf inhibitor
- Dabrafenib Serine/threonine-protein kinase B-raf inhibitor
- Dabrafenib mesylate Serine/threonine-protein kinase B-raf inhibitor
- Encorafenib Serine/threonine-protein kinase B-raf inhibitor
- LGX-806 Serine/threonine-protein kinase B-raf inhibitor
- Lifirafenib Serine/threonine-protein kinase B-raf inhibitor
- LY-3009120 Serine/threonine-protein kinase B-raf inhibitor
- Naporafenib B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
- Plixorafenib Serine/threonine-protein kinase B-raf inhibitor
- RAF-265 Serine/threonine-protein kinase B-raf inhibitor
- Regorafenib Serine/threonine-protein kinase B-raf inhibitor
- RG-7256 Serine/threonine-protein kinase B-raf inhibitor
- Sorafenib Serine/threonine-protein kinase B-raf inhibitor
- Sorafenib tosylate Serine/threonine-protein kinase B-raf inhibitor
- Tovorafenib RAF serine/threonine protein kinase inhibitor
- Vemurafenib Serine/threonine-protein kinase B-raf inhibitor
- XL-281 Serine/threonine-protein kinase B-raf inhibitor